COMPARISON OF EFFICACY AND SAFETY OF NARROWBAND UVB WITH 0.1% TACROLIMUS VS NARROWBAND UVB WITH 0.005% CALCIPOTRIOL IN TREATMENT OF VITILIGO

Early Phase 1Enrolling By InvitationNCT06880042

Dr ayesha wahid60 enrolled

Overview

Patient of stable and limited vitiligo less than 20% BSA will be recruited And evaluation of efficacy and safety of narrowband UVB with topical tacrolimus vs narrowband UVB and calcipotriol will be assessed

Evaulation of efficacy and safety of narrowband uvb and tacrolimus and NBUVB and calcipotriol in patient if stable vitiligo with body surface area less than 20% It will be assessed by VASI score and VIisual analogie scale

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Vitiligo - Macular Depigmentation Tacrolimus

Interventions

TacrolimusDRUG

Tacrolimus is calcineurin inhibitor that will act as immunomodulator

CalcipotriolDRUG

Calcipotriol is a vitamin D analogue that will act as immunomodulator

Eligibility

Sex: ALLMin age: 15 YearsMax age: 70 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: \- Localized vitiligo Age 15 to 70years Body surface upto 20% Stable more than 3 months Exclusion Criteria: * • Pregnant or lactating female patients. * Skin malignancy or any other malignant skin condition. * Photo induced or photo aggravated dermatosis like (SLE, photodermatitis, rosacea, psoriasis, pemphigus vulgaris) along with vitiligo. * Prior history of allergy to tacrolimus or calcipotriol. * Other form of treatment for vitiligo within at least 1 month.

Locations (1)

Lahore general.hospital

Lahore, Punjab Province, Pakistan

Outcomes

Primary Outcomes

VASI improvement upto 50%

Improvement in VASI score upto 50%

Time frame: 3 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.